P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.
about
Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokineticsPharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple MechanismsPharmacokinetic drug interactions in liver disease: An updateEnvironmental xenobiotics and the antihormones cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the CYP3A23 hormone response elementDevelopment of novel rifampicin-derived P-glycoprotein activators/inducers. synthesis, in silico analysis and application in the RBE4 cell model, using paraquat as substrateGenetic variability in CYP3A5 and its possible consequences.Glucose-dependent regulation of pregnane X receptor is modulated by AMP-activated protein kinase.Merck Frosst Award Lecture 1998. Molecular dissection of the human multidrug resistance P-glycoprotein.P-glycoprotein and drug therapy in organ transplantation.Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.The human CYP3A subfamily: practical considerations.Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.Herbal modulation of P-glycoprotein.Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man.Thiazide-like diuretic drug metolazone activates human pregnane X receptor to induce cytochrome 3A4 and multidrug-resistance protein 1.Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivoThe SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Interaction between saquinavir soft-gel and rifabutin in patients infected with HIVThe effect of rifampin on the pharmacokinetics of edoxaban in healthy adults.Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp.Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.Potential role of drug transporters in the pathogenesis of medically intractable epilepsy.Is autism a member of a family of diseases resulting from genetic/cultural mismatches? Implications for treatment and prevention.In Vivo Imaging of Human MDR1 Transcription in the Brain and Spine of MDR1-Luciferase Reporter Mice.Effect of anti-tuberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug.Role of efflux pumps and metabolising enzymes in drug delivery.A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine.Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition.Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications.Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite.Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs.Chlordecone, a mixed pregnane X receptor (PXR) and estrogen receptor alpha (ERalpha) agonist, alters cholesterol homeostasis and lipoprotein metabolism in C57BL/6 mice.Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.Advances in Drug Discovery and Development for Pediatric Tuberculosis.Piperine activates human pregnane X receptor to induce the expression of cytochrome P450 3A4 and multidrug resistance protein 1The drug transporter-metabolism alliance: uncovering and defining the interplay.Experimental methods and transport models for drug delivery across the blood-brain barrier.Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.
P2860
Q24656624-A7197B9B-1F10-4275-A7BC-8D7E7383B07BQ26751444-51852A8F-0145-47B0-9227-3F7DA200C536Q26774479-B0D5A70C-6C2E-45E3-9A78-64D4B7BD2149Q28369384-B0A1829C-C550-4A49-9BEB-89563B8F8740Q28535627-943192E7-1409-4586-BC53-FFCD2F80A245Q30341330-4394EC52-80CE-4AD8-8EBD-B9388C189434Q33594309-64991F53-81DD-4F07-A919-9D4168CD5947Q33699333-21735EAE-D5E1-481A-8216-73713FC97441Q33749785-E21506B1-0850-49F2-A83E-29F369CE3A93Q33843657-EC5F3800-2F99-4A83-8944-39C0285283DAQ34119161-2D8D5774-D62B-48CD-B152-771B3876F082Q34123784-79202E68-09F1-4750-97EE-C6B2C8CA52BAQ34312035-D0E2BB16-1FC1-484A-B347-7EC692925795Q34571070-4DF3C863-07EC-48DD-A782-2F56A2E84020Q34604457-7B654175-50D6-4DD1-9D5B-CFD9DB4EE80EQ34614106-8CA1BCD4-FA67-4E7C-BC4F-27768BEE2ACBQ35113118-7A6FB254-FA72-428D-87DC-6C9C9D4D7A15Q35191432-D85E7215-AF9A-4BA6-AABB-13AC7A22BA17Q35617587-CD64C955-13D4-4E74-AF3C-671EB96EC5CFQ35803924-62369D8E-4781-4DDE-AF6C-D84E314A13F4Q35807991-387F7D98-81CF-4CAC-9A58-FEE93DB76A61Q35852614-3EB335B1-5D32-4EB4-AC30-3EA555E09F2EQ36022710-0BBE9C73-8BA6-4B9E-B0B2-2DE5F7B7C1C5Q36023613-EDF3C9E1-14E3-47A6-9020-FCFC1802B7B2Q36168925-DC113586-C45E-42B6-954E-035DC66CE872Q36186153-8BEE3331-9776-41DD-AF5D-F41DB5A781B2Q36313485-08F30A88-6B78-42DD-9DB8-DC809BF6B2DBQ36316872-F671D55B-19D3-4F95-BD8E-3B0B8EB6D9CDQ36331220-CBE4AEAC-5F88-4C43-8E92-EE6049D6D4E0Q36349672-A0D229D7-AF2E-4EEF-B700-EBF53129313EQ36555922-F30EB613-2775-4AAA-82EB-D9EA2B3945FDQ36639493-94445C63-7A0F-405D-878D-821D5B1E90B8Q36795136-4A6155E2-5AB6-415D-8D2E-F1218ACACBA4Q37106874-F9D2F260-0065-48A2-8944-3A514542B45DQ37124090-70DCF7B4-2C2B-4143-8DF9-56B2577F8017Q37134041-7CC798B8-FF9E-4B7E-A273-1736C13437DAQ37179352-8E6CFB3E-CD2A-4245-A60C-0EA2A1345B9CQ37485904-559B71B7-E092-4187-B893-DE031B8EDD5EQ37698934-06AB3619-AF8C-4A40-961B-3CC64701EB70Q37910970-8345903E-0E57-4173-9388-85BFE3184BE5
P2860
P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
P-glycoprotein: a major determ ...... ome P4503A in mice and humans.
@en
P-glycoprotein: a major determ ...... ome P4503A in mice and humans.
@nl
type
label
P-glycoprotein: a major determ ...... ome P4503A in mice and humans.
@en
P-glycoprotein: a major determ ...... ome P4503A in mice and humans.
@nl
prefLabel
P-glycoprotein: a major determ ...... ome P4503A in mice and humans.
@en
P-glycoprotein: a major determ ...... ome P4503A in mice and humans.
@nl
P2093
P2860
P356
P1476
P-glycoprotein: a major determ ...... ome P4503A in mice and humans.
@en
P2093
A H Schinkel
E G Schuetz
J D Schuetz
M V Relling
P2860
P304
P356
10.1073/PNAS.93.9.4001
P407
P577
1996-04-01T00:00:00Z